MDM2 and lymphoma: Critically, unlike traditional MDM2 inhibitors, KT-253 shows no neutropenia or thrombocytopenia in advanced lymphoma/ALL patients, addressing a major toxicity limitation of occupancy-driven inhibitors [200].